Literature DB >> 15205586

Overexpression of urokinase receptor and cell surface urokinase-type plasminogen activator in the human vessel wall with different types of atherosclerotic lesions.

Martin B Steins1, Teresa Padró, Carsten Schwaenen, Sandra Ruiz, Rolf M Mesters, Wolfgang E Berdel, Joachim Kienast.   

Abstract

Urokinase-type plasminogen activator (UPA) has been implicated in a broad spectrum of pathogenic processes involved in the formation and disruption of atherosclerotic lesions. Up to now, there is no consensus on the contribution of membrane-bound UPA and its receptor CD87 (UPAR) to the development of atherosclerosis. In this study, we determined comparatively the levels of UPAR and UPAR-bound UPA in segments of human coronary and aortic vessels with different degrees of atherosclerotic lesions (macroscopically normal areas, early atherosclerotic lesions, fibrous and calcified plaques). The UPAR content increased progressively with the severity of atherosclerosis. In aortic segments, in which intima and media layers were analyzed separately, the content of UPAR in the intima significantly exceeded the levels measured in the media. Using a detergent-phase separation method with a Triton X-114-containing buffer, we could demonstrate that the levels of membrane (glycosylphosphatidylinositol)-anchored UPAR were significantly higher in the intima of early atherosclerotic lesions as well as in the cap areas of fibrous plaques compared with macroscopically normal areas. However, only 20-25% of the intimal and 30-50% of the medial glycosylphosphatidylinositol-UPAR was occupied by UPA as determined on a molar basis. These data confirm that the overexpression of UPAR in advanced atherosclerotic lesions contributes to lesion development. Whether UPAR's excess over cell surface UPA provides an additional role for this receptor in atherogenesis besides UPA-mediated proteolysis remains to be elucidated. Copyright 2004 Lippincott Williams and Wilkins

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15205586     DOI: 10.1097/01.mbc.0000114441.59147.56

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  16 in total

1.  Mechanisms of urokinase plasminogen activator (uPA)-mediated atherosclerosis: role of the uPA receptor and S100A8/A9 proteins.

Authors:  Stephen D Farris; Jie Hong Hu; Ranjini Krishnan; Isaac Emery; Talyn Chu; Liang Du; Michal Kremen; Helén L Dichek; Elizabeth Gold; Stephen A Ramsey; David A Dichek
Journal:  J Biol Chem       Date:  2011-05-02       Impact factor: 5.157

2.  Biomarkers of kidney injury and klotho in patients with atherosclerotic renovascular disease.

Authors:  Moo Yong Park; Sandra M Herrmann; Ahmed Saad; Alfonso Eirin; Hui Tang; Amir Lerman; Stephen C Textor; Lilach O Lerman
Journal:  Clin J Am Soc Nephrol       Date:  2014-12-26       Impact factor: 8.237

3.  Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.

Authors:  Ayman Samman Tahhan; Salim S Hayek; Pratik Sandesara; Jamal Hajjari; Muhammad Hammadah; Wesley T O'Neal; Heval M Kelli; Ayman Alkhoder; Nima Ghasemzadeh; Yi-An Ko; Hiroshi Aida; Mohamad Mazen Gafeer; Naser Abdelhadi; Kareem Hosny Mohammed; Keyur Patel; Shipra Arya; Jochen Reiser; Viola Vaccarino; Laurence Sperling; Arshed Quyyumi
Journal:  Atherosclerosis       Date:  2017-06-08       Impact factor: 5.162

4.  Plasminogen mediates the atherogenic effects of macrophage-expressed urokinase and accelerates atherosclerosis in apoE-knockout mice.

Authors:  Michal Kremen; Ranjini Krishnan; Isaac Emery; Jie Hong Hu; Katherine I Slezicki; Alyssa Wu; Kun Qian; Liang Du; Abigail Plawman; April Stempien-Otero; David A Dichek
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-28       Impact factor: 11.205

5.  A novel signaling pathway: fibroblast nicotinic receptor alpha1 binds urokinase and promotes renal fibrosis.

Authors:  Guoqiang Zhang; Kelly A Kernan; Alison Thomas; Sarah Collins; Yumei Song; Ling Li; Weizhong Zhu; Renee C Leboeuf; Allison A Eddy
Journal:  J Biol Chem       Date:  2009-08-18       Impact factor: 5.157

6.  Plasmin promotes foam cell formation by increasing macrophage catabolism of aggregated low-density lipoprotein.

Authors:  Abigail S Haka; Inna Grosheva; Rajesh K Singh; Frederick R Maxfield
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-05-23       Impact factor: 8.311

Review 7.  Urokinase and its receptors in chronic kidney disease.

Authors:  Guoqiang Zhang; Allison A Eddy
Journal:  Front Biosci       Date:  2008-05-01

8.  Hepatic Overexpression of Soluble Urokinase Receptor (uPAR) Suppresses Diet-Induced Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient (LDLR-/-) Mice.

Authors:  Jan Larmann; Kerstin Jurk; Henrike Janssen; Martin Müller; Christine Herzog; Anika Lorenz; Martina Schmitz; Jerzy-Roch Nofer; Gregor Theilmeier
Journal:  PLoS One       Date:  2015-08-27       Impact factor: 3.240

9.  Serum Soluble Urokinase-Type Plasminogen Activator Receptor Is Associated with Low Left Ventricular Ejection Fraction and Elevated Plasma Brain-Type Natriuretic Peptide Level.

Authors:  Shu-Ichi Fujita; Suguru Tanaka; Daichi Maeda; Hideaki Morita; Tomohiro Fujisaka; Yoshihiro Takeda; Takahide Ito; Nobukazu Ishizaka
Journal:  PLoS One       Date:  2017-01-30       Impact factor: 3.240

10.  Urokinase receptor counteracts vascular smooth muscle cell functional changes induced by surface topography.

Authors:  Yulia Kiyan; Kestutis Kurselis; Roman Kiyan; Hermann Haller; Boris N Chichkov; Inna Dumler
Journal:  Theranostics       Date:  2013-07-03       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.